![Steffen Walter](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Steffen Walter
Chief Operating Officer at
IMMATICS N.V.
Net worth: 115 100 $ as of 31/05/2026
Profile
Steffen Walter is the founder of Immatics US, Inc., founded in 2015, holding the title of Chief Scientific Officer since 2015.
Dr. Walter currently holds the position of Chief Operations Officer at Immatics Biotechnologies GmbH since 2023, with the job starting in 2005 and ongoing.
Dr. Walter also holds the position of Chief Operations Officer at Immatics NV since 2023, with the job starting in 2020 and ongoing.
Dr. Walter completed a doctorate degree at Eberhard Karls Universität Tübingen.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
IMMATICS N.V. 0.01% | 18/03/2026 | 10,000 ( 0.01% ) | 115 100 $ | 31/05/2026 |
Steffen Walter active positions
| Companies | Position | Start |
|---|---|---|
| IMMATICS N.V. | Chief Operating Officer | 21/03/2023 |
Immatics US, Inc.
 Immatics US, Inc. BiotechnologyHealth Technology Develops adoptive cell therapies for treatment of cancer | Founder | 01/01/2015 |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer | Chief Operating Officer | 21/03/2023 |
Training of Steffen Walter
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
19
1st degree connections
4
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer | Health Technology |
Eberhard Karls Universität Tübingen
 Eberhard Karls Universität Tübingen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Develops adoptive cell therapies for treatment of cancer | Health Technology |
Immatics NV
 Immatics NV Pharmaceuticals: MajorHealth Technology Engages in developing immunotherapies for cancer treatments | Health Technology |
- Stock Market
- Insiders
- Steffen Walter
